KR20160030206A - 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 - Google Patents

사구체 질환을 치료하는데 사용하기 위한 로스마피모드 Download PDF

Info

Publication number
KR20160030206A
KR20160030206A KR1020167002417A KR20167002417A KR20160030206A KR 20160030206 A KR20160030206 A KR 20160030206A KR 1020167002417 A KR1020167002417 A KR 1020167002417A KR 20167002417 A KR20167002417 A KR 20167002417A KR 20160030206 A KR20160030206 A KR 20160030206A
Authority
KR
South Korea
Prior art keywords
nicotinamide
phenyl
cyclopropylcarbamoyl
dimethylpropyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167002417A
Other languages
English (en)
Korean (ko)
Inventor
데니스 스프레쳐
로버트 니콜라스 윌레트
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드
Publication of KR20160030206A publication Critical patent/KR20160030206A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020167002417A 2013-07-10 2014-07-08 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 Withdrawn KR20160030206A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844491P 2013-07-10 2013-07-10
US61/844,491 2013-07-10
PCT/EP2014/064508 WO2015004089A1 (en) 2013-07-10 2014-07-08 Losmapimod for use in treating glomerular disease

Publications (1)

Publication Number Publication Date
KR20160030206A true KR20160030206A (ko) 2016-03-16

Family

ID=51134104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002417A Withdrawn KR20160030206A (ko) 2013-07-10 2014-07-08 사구체 질환을 치료하는데 사용하기 위한 로스마피모드

Country Status (9)

Country Link
US (1) US9707219B2 (enExample)
EP (1) EP3019168A1 (enExample)
JP (1) JP2016523943A (enExample)
KR (1) KR20160030206A (enExample)
CN (1) CN105358148A (enExample)
AU (1) AU2014289296A1 (enExample)
CA (1) CA2917277A1 (enExample)
RU (1) RU2015156417A (enExample)
WO (1) WO2015004089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
GB201821138D0 (en) * 2018-12-21 2019-02-06 Benevolentai Bio Ltd Compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101058292B1 (ko) 2002-02-12 2011-08-22 글락소스미스클라인 엘엘씨 Ｐ38 억제제로 유용한 니코틴아미드 유도체
KR20070074576A (ko) * 2004-10-29 2007-07-12 코와 가부시키가이샤 사구체 질환 치료제
GB0612026D0 (en) * 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
EP2874627A1 (en) * 2012-07-17 2015-05-27 Glaxosmithkline LLC Nicotinamide derivate in the treatment of acute coronary syndrome

Also Published As

Publication number Publication date
AU2014289296A1 (en) 2016-02-04
US9707219B2 (en) 2017-07-18
CN105358148A (zh) 2016-02-24
WO2015004089A1 (en) 2015-01-15
RU2015156417A (ru) 2017-08-15
CA2917277A1 (en) 2015-01-15
JP2016523943A (ja) 2016-08-12
US20160220550A1 (en) 2016-08-04
EP3019168A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
JP2023062198A (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
CA2465759A1 (en) Method for administering birb 796 bs
RS61053B1 (sr) Pоstupak za sprečavanje i / ili lečenje kognitivnog oštećenja povezanog sa starenjem i neuroinflamacijom
KR20160030206A (ko) 사구체 질환을 치료하는데 사용하기 위한 로스마피모드
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
Joos et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
JP2013536206A5 (enExample)
KR102725563B1 (ko) 인돌 화합물을 사용한 통증 또는 간질성 방광염의 치료 방법
JP2015509931A (ja) 医薬的な組み合わせ
WO2013054940A1 (ja) 脱髄疾患の治療薬及び予防薬
AU2021221333B2 (en) Novel medicament for treating inflammatory disease
JP2005505605A (ja) 前痴呆状態におけるロスバスタチン
WO2023076404A1 (en) Methods for treating systemic lupus erythematosus
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
IL293205A (en) Masitinib use for the treatment of eosinophilic asthma
JP2005314347A (ja) 疼痛抑制剤
JPWO2020004404A1 (ja) ＩＬ−１β阻害薬
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
RU2791025C2 (ru) Способ лечения боли или интерстициального цистита с использованием индольного соединения
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
AU2025271047A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
HK40049577B (en) Indole compound for treating interstitial cystitis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid